Riverain Medical has received FDA approval for the latest version of the OnGuard Chest X-ray Computer-Aided Detection (CAD) technology. The new version of CAD technology is expected to increase 50% relative improvement in sensitivity and 73% reduction in false positive marks.
Riverain Medical’s OnGuard identifies solitary pulmonary nodules that may represent early-stage lung cancer on an existing chest X-ray. It uses pattern recognition and machine learning technology to detect nodules. Well centered, scaled markers are then placed around regions of interest that may be early-stage lung cancer.
Riverain Medical said that, as OnGuard utilises the existing digital chest X-ray, there is no additional radiation dose, patient procedure, hardware or stand-alone workstation needed to integrate the technology into any radiology department.
Charles White, professor and vice chairman of radiology at the University of Maryland School of Medicine, said: “Our published studies demonstrate that OnGuard can detect up to 50% of the lung cancers that were missed in the initial interpretation. OnGuard provides physicians with a tool to help identify suspicious nodules in the lungs earlier.”
Diane Hirakawa, CEO and chairman of Riverain Medical, said: “OnGuard can make a difference in the fight against lung cancer. This technology can improve the detection of lung cancer in its earliest stages when treatments are most effective.”